Literature DB >> 1081233

Isolation and identification of alpha1-antitrypsin as a component of normal and malignant human breast and other tissues.

S S Twining, A S Brecher.   

Abstract

Alpha1-Antitrypsin has been detected using radial immunodiffusion in the 90,000g supernatant fraction of malignant and adjacent normal human breast, colon, and anal tissue, as well as malignant lung, stomach, and ileum. Immobilized chymotrypsin, bound to Sepharose or Affi-Gel 10 has been utilized to separate 11 peaks of antiproteolytic activity by affinity chromatography of normal and malignant human breast tissue extracts. Glycoproteins are associated with eight of the peaks. Peak 1 contains predominantly alpha1-antitrypsin in addition to a minor component. The purification of the inhibitors, as judged by disc gel electrophoresis, is extensive. In some peaks, only one or two protein bands are observed, suggesting that affinity chromatography on Sepharose- or Affi-Gel 10-chymotrypsin might be used for the isolation of alpha1-antitrypsin and other inhibitors in preparative amounts.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1081233     DOI: 10.3181/00379727-150-38981

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  3 in total

1.  Comparison of conventional molecular and whole-genome sequencing methods for subtyping Salmonella enterica serovar Enteritidis strains from Tunisia.

Authors:  Boutheina Ksibi; Sonia Ktari; Houcemeddine Othman; Kais Ghedira; Sonda Maalej; Basma Mnif; Mohamed Salah Abbassi; Laetitia Fabre; Faouzia Rhimi; Simon Le Hello; Adnene Hammami
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-08       Impact factor: 3.267

2.  Low molecular weight proteinase inhibitors. I. Extraction and identification of activity from normal and malignant human breast tissues.

Authors:  B Waxler; F H Wezeman
Journal:  Br J Exp Pathol       Date:  1983-06

3.  Malignant mesothelioma.

Authors:  E Heyderman; P D Ridley
Journal:  J R Soc Med       Date:  1989-09       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.